Continuing Education Webinars

W H A T   Y O U   W I L L   L E A R N

How Immunotherapy Can Make A Difference For Your Patients

As a family veterinarian, you’re most often the first encounter when a dog is diagnosed with cancer. Arm yourself with the latest information on the treatment options available to pet owners today in this 30-minute RACE-approved webinar.

Osteosarcoma accounts for up to 85 percent of all primary bone tumors in dogs. Yet, there have been relatively few advancements in treatment options to improve patient outcomes. Until now, treatment options have been limited to therapeutic amputation to relieve pain and remove tumor burden. Without further medical intervention such as 4-6 dose carboplatin, median survival time for dogs with no metastatic disease at diagnosis has been shown to be 134 days -4 months. With carboplatin, median survival time has been shown to be 9 months.

The American Cancer Society website defines Immunotherapy as treatment that uses certain parts of a person’s immune system to fight diseases such as cancer. Immunotherapies that have achieved considerable success in the human health arena include checkpoint inhibitors and adoptive cell therapies such as chimeric antigen receptor (CAR) T cell therapies and TIL (tumor infiltrating lymphocytes). These are finally becoming available in veterinary medicine.

In this program we will discuss the history and background of immunotherapy development, learn how to identify and distinguish between current cancer immunotherapy technologies, and discuss the conduct of the USDA-approved ELIAS ECI® adoptive cell therapy protocol.

Learning Objectives:

  1. Demonstrate a basic understanding of the history and background of immunotherapy development for the treatment of cancer
  2. Identify and distinguish between cancer vaccines and adoptive cell therapies
  3. Understand the ELIAS Cancer Immunotherapy (ECI®) protocol

Register for an Upcoming Session

ON DEMAND

Coming Soon!

What Vets Are Saying About ECI®

“I really think that there is strong evidence that the ELIAS procedure benefited these dogs, substantially
and on average, based on that median survival. I will also point out that every single piece of the ELIAS
immunotherapy process is extremely well supported in the scientific literature across multiple species.”

Jeffrey Bryan, DVM, DACVIM (Oncology), University of Missouri

“There’s going to be a never-ending irreversible limitation of what autologous vaccine alone can do, which is why I’m attracted to the ECI product because of the activated T cell component. I don’t think that any of
these products or autologous vaccines that are out there today are that much different or are going to offer that much significant difference. Whereas I think ECI has some clear improvements and should
result in better results and better outcomes.”

K. Ann Jeglum, VMD, DACVIM (Oncology), Veterinary Oncology Services and Research Center

Make a Difference For Your Patients